• Novogenia launched the expanded MGT Plus methylation genetic test in the US on Aug. 25, 2026.
• Rollout extends its joint product pipeline with US partner 10X Health, strengthening cross-border collaboration in genetic analysis.
• Test broadens coverage to 27 genes, targeting a wider readout of methylation-related pathways than typical consumer offerings.
• Management positioned the launch as a lever to expand international product reach in the fast-growing direct-to-consumer genetic testing market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novogenia AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2387718_en) on August 25, 2026, and is solely responsible for the information contained therein.